Sugi Predict

Sugi Predict / Compounds / SCHEMBL315542

SCHEMBL315542

SCHEMBL315542

CC(=O)N1CCC(CN)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NCF1 P14598 1/20 0.52
▸ PLG P00747 1/20 0.43
▸ PLAT P00750 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ EPHX2 P34913 5/20 0.43
▸ EPHX1 P07099 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CHRM2 P08172 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PIK3CD O00329 1/20 0.39
▸ TPSAB1 Q15661 1/20 0.39
▸ TPSD1 Q9BZJ3 1/20 0.39
▸ TPSG1 Q9NRR2 1/20 0.39
▸ QDPR P09417 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6044484 0.98 NCF1 (0.50) NCF1PLGPLATLMNAEPHX2
SCHEMBL15045164 0.89 CHRM1 (0.44) NCF1LMNAEPHX2EPHX1CHRM2
SCHEMBL864290 0.88 NCF1 (0.43) NCF1PLGPLATLMNAEPHX2
SCHEMBL864289 0.88 NCF1 (0.43) NCF1PLGPLATLMNAEPHX2
SCHEMBL12507060 0.88 NCF1 (0.43) NCF1PLGPLATLMNAEPHX2
Trifluoroacetic Acid SCHEMBL16039131 0.88 DPP8 (0.46) NCF1PLGPLATLMNAEPHX2
SCHEMBL6043115 0.83 CHRM2 (0.44) EPHX2EPHX1CYP1A2TDP1CHRM2
Hydrochloric Acid SCHEMBL6044689 0.82 CHRM2 (0.43) EPHX2EPHX1CYP1A2TDP1CHRM2
SCHEMBL14013049 0.81 PLG (0.40) NCF1PLGPLATLMNACYP1A2
SCHEMBL15398791 0.81 LMNA (0.48) NCF1PLGPLATLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445501-B2 Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines TAKEDA GMBH (DE) 2013-05-21 — — US claimed
EP-2536731-A1 SUBSTITUTED SPIROINDOLINONES F. Hoffmann-La Roche AG (CH) 2012-12-26 — — EP claimed
US-8288431-B2 Substituted spiroindolinones HOFFMANN-LA ROCHE INC. (US) 2012-10-16 — — US claimed
EP-2245033-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2011-08-31 — — EP claimed
EP-2245033-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-03 — — EP claimed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 — — US claimed
WO-2009106441-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 — — WO claimed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 — — EP claimed
US-12331035-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-06-17 — — US disclosed
WO-2025068371-A1 INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE PHILIPPS-UNIVERSITÄT MARBURG (DE) 2025-04-03 — — WO disclosed
EP-4050006-B1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2025-01-01 — — EP disclosed
CN-113923988-B Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same 爱彼特生物制药公司 2024-12-13 — — CN disclosed
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2024-11-21 — — US disclosed
CN-118812521-A Benzo heterocyclic compound and application thereof 中科中山药物创新研究院 2024-10-22 — — CN disclosed
CN-1117960-A Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides CIBA GEIGY AG (CH) 1996-03-06 — — CN disclosed
EP-0199400-B1 Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines JANSSEN PHARMACEUTICA N.V. (BE) 1990-09-26 — — EP disclosed
US-4826848-A Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines JANSSEN PHARMACEUTICA N.V. (BE) 1989-05-02 — — US disclosed
US-4749702-A PARKINSON*S DISEASE, ENTEROKINESIA JANSSEN PHARMACEUTICA N. V. (BE) 1988-06-07 — — US disclosed
US-4689330-A PARKINSON DISEASE JANSSEN PHARMACEUTICA N.V. (BE) 1987-08-25 — — US disclosed
EP-0199400-A2 Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines JANSSEN PHARMACEUTICA N.V. (BE) 1986-10-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, TYK2 NCF1 666/4885PLG 4247/4885PLAT 3021/4885
US-12331035-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 NCF1 2944/4885PLG 3716/4885PLAT 3906/4885
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE CDK3, CDK1, CDK2 NCF1 3837/4885PLG 2009/4885PLAT 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.